Breaking News Instant updates and real-time market news.

GMED

Globus Medical

$34.23

2.39 (7.51%)

07:59
11/10/17
11/10
07:59
11/10/17
07:59

Globus Medical upgraded to Neutral from Underperform at BofA/Merrill

BofA/Merrill analyst Bob Hopkins upgraded Globus Medical to Neutral and raised its price target to $37 from $23 based on positive physician feedbak on its new robotic platofrm.

  • 28

    Nov

GMED Globus Medical
$34.23

2.39 (7.51%)

08/17/17
PIPR
08/17/17
NO CHANGE
Target $34.5
PIPR
Overweight
Globus Medical news today a 'clear positive,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says that given fear among investors that the system would not receive approval for a long time, this morning's announcement from Globus Medical that the Excelsius GPS robotics system received 510k approval is a "clear positive." The analyst adds that he continues to receive favorable commentary from clinicians about the Globus' robotic system. He recommends buying the stock at current levels.
09/07/17
BTIG
09/07/17
INITIATION
BTIG
Buy
Globus Medical initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started coverage of Globus with a $37 price target and a Buy rating. The analyst says that the company has largely resolved the issues that had plagued its sales force, while its "best-in-class profitability profile has remained strong." Zimmerman says that the recent drop in the stock has created a buying opportunity, and he thinks it has multiple positive catalysts, including "rapid new product introductions, favorable 2H17 comps, improving market dynamics in spine, and the best EBITDA margins in spine."
09/26/17
NEED
09/26/17
INITIATION
NEED
Hold
Globus Medical initiated with a Hold at Needham
Needham analyst Michael Matson initiated Globus Medical with a Hold citing fair valuation and high 2018 Street estimates.
10/10/17
NEED
10/10/17
NO CHANGE
Target $27
NEED
Strong Buy
K2M Group price target lowered to $27 from $29 at Needham
Needham analyst Mike Matson lowered his price target on K2M Group (KTWO) to $27 following the company's disappointing Q3 pre-announcement and a cut in FY17 revenue guidance. Matson maintains his Strong Buy rating to reflect the company's strong product cycle, potential to be acquired, and discount valuation. He attributes the Q3 shortfall for K2M to delays with signing new distributors because of longer due diligence process and weaker degenerative and deformity procedure growth. The analyst warns that other spine companies - including Globus Medical (GMED) and NuVasive (NUVA) - may be hampered by these constraints.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.